Company intelligence / Profile preview

SignatureDx

Pittsburgh, Pennsylvania, United Statessignaturedx.com ↗

Ownership: Private
Development stage: Commercial

Overview

SignatureDx has developed noninvasive diagnostic tests using cell-free DNA from maternal blood samples to detect genetic conditions in pregnancies and other complex diseases. Their technology aims to provide safer alternatives to invasive prenatal testing methods like amniocentesis, with broader applications in early disease detection across multiple indications. The company's approach leverages proprietary lab techniques and patented analytical methods centered around cfDNA methylation patterns.

Therapeutic areas: Rare DiseasesNephrologyWomen's Health
Modalities: Diagnostic testLiquid biopsyCell-free DNA analysis
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on SignatureDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignatureDx.

Explore the full profile